Mitochondria are best known for their role in cellular energy production, but modern research has revealed that they are much more than cellular power plants.They participate in metabolism, stress signaling, gene regulation, reactive-oxygen-species balance, apoptosis, and communication between different parts of the cell.
That has made mitochondrial biology a major area of modern peptide research. Two compounds that frequently appear in that conversation are MOTS-C and SS-31.
They are often grouped together because they both involve mitochondria. Scientifically, however, they approach mitochondrial biology from very different directions.
What Is MOTS-C?
MOTS-C is a 16-amino-acid mitochondrial-derived peptide encoded within the mitochondrial genome. It was first described in 2015 in research investigating mitochondrial signaling and metabolic regulation. Early experiments found that MOTS-C influenced cellular metabolic pathways and glucose utilization in experimental models.
That alone made MOTS-C unusual. Most of the proteins and peptides involved in cellular regulation are encoded by DNA located inside the nucleus. MOTS-C belongs to a relatively newer class of molecules demonstrating that mitochondrial DNA can also encode biologically active signaling peptides.
Researchers later reported another particularly interesting behavior: under metabolic stress, MOTS-C can move into the nucleus and influence nuclear gene expression through pathways involving AMPK.
In simplified terms, MOTS-C research is partly about communication. The mitochondria are not simply producing energy. They may also be sending molecular signals that help the rest of the cell respond to changes in metabolic conditions.
That has made MOTS-C an interesting research target in areas involving cellular metabolism, mitochondrial signaling, metabolic stress, skeletal muscle biology, and age-associated changes in cellular function.
But there is an important distinction between an interesting biological mechanism and an established clinical application.
Much of the MOTS-C literature remains preclinical. In its 2026 evaluation of MOTS-C-related substances for pharmacy compounding, the FDA reported that it had not identified human exposure data involving drug products containing MOTS-C and stated that important human safety information remains unavailable.
That leaves researchers with a fascinating biological signal—and a large number of unanswered questions.
What Is SS-31?
SS-31 takes a completely different approach.
Also known in scientific development as elamipretide, SS-31 is a synthetic mitochondria-targeted tetrapeptide. Instead of being encoded by mitochondrial DNA, SS-31 was designed to interact directly with mitochondrial structures. One of the major areas of SS-31 research involves the inner mitochondrial membrane and a phospholipid called cardiolipin.
Cardiolipin is an important component of the inner mitochondrial membrane and contributes to the organization of proteins involved in oxidative phosphorylation and cellular energy production.
Experimental work investigating SS-31 has identified interactions involving cardiolipin-associated mitochondrial proteins and components involved in ATP production.
That means SS-31 research generally starts from a different question than MOTS-C research.
With MOTS-C, researchers are examining a mitochondrial-derived signal.
With SS-31, researchers are examining a peptide designed to interact with mitochondrial structure and bioenergetic machinery.
Both involve mitochondria—but at very different levels.
MOTS-C vs. SS-31: The Key Difference
The simplest way to think about the distinction is this:
MOTS-C:
A mitochondrially encoded signaling peptide being studied for how mitochondria communicate with other cellular systems and respond to metabolic stress.
SS-31:
A synthetic mitochondria-targeted peptide being studied for interactions involving the inner mitochondrial membrane, cardiolipin, oxidative phosphorylation, and mitochondrial bioenergetics.
One is largely a story about mitochondrial signaling. The other is largely a story about mitochondrial structure and function. That distinction is exactly what makes comparing them useful.
SS-31 Has Also Reached a Very Different Stage of Development
There is another major difference between the two compounds.
SS-31/elamipretide has progressed substantially further into clinical development.
In September 2025, the FDA granted accelerated approval to Forzinity (elamipretide) for Barth syndrome in patients weighing at least 30 kg. The approval was based on a measure involving knee-extensor muscle strength that the FDA determined was reasonably likely to predict clinical benefit, with a confirmatory post-approval trial required. That is an important milestone in mitochondrial medicine.
Why Researchers Study Both
Mitochondrial dysfunction can involve much more than a single pathway. A cell may experience changes in energy production, membrane organization, oxidative stress, metabolic signaling, gene expression, or communication between mitochondria and the nucleus.
MOTS-C and SS-31 allow researchers to approach that biology from different directions.
MOTS-C raises questions about how mitochondrial-derived signals influence the larger cellular environment. SS-31 raises questions about how directly targeting mitochondrial structures can influence bioenergetics and cellular responses. That is why calling both simply “mitochondrial peptides” tells only part of the story. Their real scientific value lies in how differently they interact with mitochondrial biology.
THE TAKEAWAY
MOTS-C and SS-31 share a mitochondrial connection, but they are not interchangeable research compounds. MOTS-C represents an emerging area of mitochondrial-to-cell signaling research.
SS-31 represents a more advanced mitochondria-targeting research platform that has also led to an FDA-approved pharmaceutical product in a specific rare disease. Same organelle. Very different scientific stories.
0 comments